Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
LEAK: Call of Duty 2025 Will Feature Remastered Black Ops 2 Maps
Xi’s Micron Ban Shows China’s Limited Options to Hit Back at US
Use Your FC 24 Founders Evolution On These Players Only
WWE Superstar Mia Yim is heading to WWE 2K23
Activists spurred by affirmative action ruling sue Harvard over legacy admissions
SpaceX hints next Starship launch attempt could be soon
Get This Refurbished Lenovo ThinkCentre M92P for Under $650
Get a refurb iPad 6 and Beats Flex headphones for $195